Gilead Announces New Sustained Viral Response Data For Sofosbuvir-Based Regimens In Genotype 3-Infected Hepatitis C Patients
Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from two
studies, the Phase 3 VALENCE study and the Phase 2 LONESTAR-2 study,
evaluating the investigational once-daily nucleotide analogue sofosbuvir
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.